PSMG2

Across TCGA pan-cancer cohorts, PSMG2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PSMG2 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PSMG2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PSMG2 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

LUAD, GBM, and LSCC are the cancer types where PSMG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	0.306	0.866	.004	36	view →
GBM	DFS	Median	All	0.323	0.207	.012	20	view →
LSCC	DFS	Median	II,III,IV	1.000	0.419	.008	16	view →
COAD	DFS	Quartile	II,III,IV	0.883	1.000	.026	12	view →
PDAC	OS	Tertile	II,III,IV	0.715	0.406	.002	11	view →
CCRCC	DFS	Median	III,IV	0.123	0.782	.028	10	view →
HNSC	DFS	Median	III,IV	0.937	1.000	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PSMG2–LUAD (OS)

Open the LUAD breakdown →